Mouse and large-animal toxicology studies of twelve antitumor agents: Relevance to starting dose for Phase I clinical trials

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00254979PMID 116778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents.

  1979cited by this paper
• Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.

  1975cited by this paper
• Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology.

  1973cited by this paper
• Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man.

  1972cited by this paper
• Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man.

  1972cited by this paper
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

  1966cited by this paper

• Transformative Paths: Preclinical Drug Formulation and Delivery Approaches in Development.

  2025cites this paper
• The role of NMDARs in the anesthetic and antidepressant effects of ketamine

  2023cites this paper
• Pharmacokinetics in Drug Development

  2016cites this paper
• A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond

  2016cites this paper
• Supplementation of fish oil augments efficacy and attenuates toxicity of 5-fluorouracil in 1,2-dimethylhydrazine dihydrochloride/dextran sulfate sodium-induced colon carcinogenesis

  2014cites this paper
• Development of Preclinical Formulations for Toxicology Studies

  2013cites this paper
• Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials

  2012cites this paper
• Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials

  2011cites this paper
• Recent advances and novel strategies in pre-clinical formulation development: an overview.

  2011cites this paper
• Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials

  2010cites this paper
• Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.

  2010cites this paper
• The war on cancer: have we won the battle but lost the war?

  2010cites this paper
• [Development of new substances in oncology. Many problems and some answers].

  2008cites this paper
• Spectroscopic Identification of Binding Modes of Anthracene Probes and DNA Sequence Recognition†

  2006cites this paper
• Part I General Principles and Controversial Issues in Dose-Findings 3

  2006cites this paper
• Overview of Phase I Trials

  2005cites this paper
• Choice of starting dose and escalation for phase I studies of antitumor agents

  2004cites this paper
• Antitumor drug toxicity in tumor-free and tumor-bearing mice

  2004cites this paper
• Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice

  2004cites this paper
• Phase I trials in clinical oncostatic pharmacology

  2004cites this paper
• High-dose ibuprofen for reduction of striatal infarcts during middle cerebral artery occlusion in rats.

  2003cites this paper
• Estimating the starting dose for entry into humans: principles and practice

  2002cites this paper
• Interspecies Scaling of Maximum Tolerated Dose of Anticancer Drugs: Relevance to Starting Dose for Phase I Clinical Trials

  2001cites this paper
• A Strategy for Primary High Throughput Cytotoxicity Screening in Pharmaceutical Toxicology

  2000cites this paper
• Of (only) mice and men

  1999cites this paper
• Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

  1999cites this paper
• Clinical trials of antitumor agents: experimental design and timeline considerations.

  1997cites this paper
• Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.

  1996cites this paper
• The Use of the Dog in Toxicity Tests on Pharmaceutical Compounds

  1993cites this paper
• Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.

  1993cites this paper
• New approaches in preclinical and clinical pharmacokinetics.

  1993cites this paper
• The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies.

  1992cites this paper
• Phase I trial of Perrimustine, a new cysteamine (2‐chloroethyl) nitrosourea: an intrapatient escalation scheme

  1992cites this paper
• Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.

  1991cites this paper
• Statistical requirements of phase I studies.

  1990cites this paper
• Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.

  1990cites this paper
• Design and analysis of phase I clinical trials.

  1989cites this paper
• Effects of cis‐diamminedichloroplatinum (II) upon haemopoietic progenitors and the haemopoietic microenvironment in mice

  1988cites this paper
• The main steps in the development of anticancer agents.

  1988cites this paper
• "Design of phase I and II clinical trials in cancer: a statistician's view.".

  1987cites this paper
• Phase I pharmacologic study of a new Vinca alkaloid: navelbine.

  1985cites this paper
• Design of phase I and II clinical trials in cancer: a statistician's view.

  1984cites this paper
• Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.

  1982cites this paper
• Effects of cisplatin on different haemopoietic progenitor cells in mice.

  1982cites this paper
• Analogs of pyrimidine and purine mononucleotide precursors as metabolic inhibitors.

  1981cites this paper
• The Cancer Therapy Evaluation Program of the National Cancer Institute.

  1981cites this paper
• Animal toxicology for early clinical trials with anticancer agents.

  1981cites this paper
• Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice

  1980cites this paper